India, March 16 -- Sutro Biopharma Inc. (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRaME-O1 trial with luveltamab tazevibulin (luvelta) in patients with platinum resistant ovarian cancer (PROC) at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. In the study, luvelta demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer across all levels of Folate Receptor-a or FRa expression of 25% or greater, including an improved overall response rate (ORR), a low discontinuation rate, and a consistent safety profile across dose levels. Based on the findings, Sutro selected the optimized dose of luvelta: 5.2 mg/kg + G-CSF for t...